CVC Capital Partners and Groupe Bruxelles Lambert have moved from interest to action with a €10.7 billion cash offer for Recordati. The bid would take one of Italy's strongest pharma groups private at a time when rare-disease assets are drawing serious long-term capital.
The offer puts a clear price on a company that public markets have not treated like a distressed asset, because Recordati is not one. The consortium is offering €51.29 per share ex-dividend, or €52.00 including the 2025 dividend balance, through Respighi BidCo, with the goal of buying the whole company and delisting it from Euronext Milan. According to a Reuters report on May 22, the price represents a 12.89 percent premium to Recordati's closing price on March 25, the day before CVC's interest became public.
The support of Rossini, Recordati's existing controlling shareholder, changes the shape of the deal. Rossini owns 46.82 percent of the company and has agreed to tender its stake, giving the consortium almost half the register before minority investors make a decision. That does not make the outcome automatic, but it does make the offer difficult to ignore.
Recordati's appeal is easy to understand. The company reported €2.62 billion in 2025 revenue, up 11.8 percent, and its rare-disease business reached €1.08 billion. Like-for-like rare-disease growth at constant exchange rates was 16.6 percent, helped by strong demand in endocrinology and oncology. Isturisa, its treatment for Cushing's syndrome, generated €262.8 million in 2025 sales, up from €203.6 million a year earlier. That is the kind of growth profile private equity likes: specialist products, clear medical need, and room for acquisitions.
Why private ownership makes sense here
The argument for taking Recordati private is not about fixing a broken company. It is about giving management room to spend more aggressively on research, licensing and M&A without having every investment filtered through the next earnings call. Rare-disease drug development takes time. It also rewards companies that can build focused commercial teams around small patient populations and high-value therapies.
That matters because European pharma dealmaking has already been busy this year. Angelini agreed to buy Catalyst Pharmaceuticals for $4.1 billion, gaining a stronger U.S. rare-disease footprint. Chiesi agreed to acquire KalVista Pharmaceuticals for about $1.9 billion, adding an oral therapy for hereditary angioedema. Recordati is different because the buyer group wants to remove a profitable listed company from the market entirely, not simply bolt on a new product or geography.
For founders and investors, the signal is uncomfortable but useful. Public markets still offer liquidity and visibility, but they do not always reward businesses that need years of reinvestment before the next growth curve becomes obvious. If patient capital can offer a fair valuation and fewer public-market constraints, a take-private can become a credible alternative to waiting for a multiple re-rating that may never arrive.
The backers are part of the story
CVC and GBL are not acting alone. Funds linked to the Abu Dhabi Investment Authority and the Canada Pension Plan Investment Board are also involved, while Recordati chairman Andrea Recordati is expected to roll his stake into the new structure. That mix matters. Sovereign wealth funds and pension plans are not usually looking for quick flips. Their participation suggests confidence that rare-disease pharma can compound over a longer holding period.
GBL is committing about €1.3 billion, making the transaction a major step in its move toward more private assets. For the Belgian investment group, Recordati offers exposure to healthcare, Europe and specialist medicine in one deal. For CVC, which has been connected to the controlling shareholder since 2018, the bid is a chance to turn influence into full control and push the next phase away from the public market spotlight.
Minority shareholders now have the hard choice
The premium is meaningful, but not generous enough to end the debate. A 12.89 percent uplift may look modest for a company with strong margins and a rare-disease platform that is still expanding. Minority shareholders have to weigh that against the practical alternative: staying invested in a company that may become private and far less liquid if the delisting succeeds.
The offer is expected to complete in late 2026, subject to regulatory approvals and the tender process. The consortium needs enough minority participation to reach its acceptance threshold, so the next stage will show whether investors see the bid as a fair cash exit or as an early move on a company with more upside ahead.
The broader implication reaches beyond Recordati. If this deal closes, it will reinforce the idea that high-quality European healthcare companies can be worth more to private owners than to public shareholders. For founders, the lesson is not that an IPO is broken. It is that the best exit is the one that matches the company's capital needs. Recordati spent a century building defensible products and a global rare-disease platform. The consortium is betting that the next stage can move faster without the public spotlight.
Also read: Qwen3.7-Max prioritizes agent reliability over open weights • Ukraine's ground robot held a position for 45 days • Zcash breakout tests institutional appetite for privacy
